Fundamental Analysis of AKERO THERAPEUTICS INC(NASDAQ:AKRO) stock

Fundamental Rating

Overall AKRO gets a fundamental rating of 2 out of 10. We evaluated AKRO against 588 industry peers in the Biotechnology industry. AKRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AKRO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

AKRO had negative earnings in the past year.

In the past year AKRO has reported a negative cash flow from operations.

In the past 5 years AKRO always reported negative net income.

In the past 5 years AKRO always reported negative operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -26.15%, AKRO is doing good in the industry, outperforming 76.11% of the companies in the same industry.

AKRO's Return On Equity of -28.35% is amongst the best of the industry. AKRO outperforms 82.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.15%
ROE	-28.35%
ROIC	N/A

ROA(3y)-36.37%

ROA(5y)-33.96%

ROE(3y)-40.75%

ROE(5y)-37.37%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKRO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, AKRO has more shares outstanding

The number of shares outstanding for AKRO has been increased compared to 5 years ago.

The debt/assets ratio for AKRO is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 16.77 indicates that AKRO is not in any danger for bankruptcy at the moment.

AKRO's Altman-Z score of 16.77 is amongst the best of the industry. AKRO outperforms 91.64% of its industry peers.

AKRO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.

AKRO has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: AKRO underperforms 60.07% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	16.77

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

AKRO has a Current Ratio of 29.27. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 29.27, AKRO belongs to the best of the industry, outperforming 97.95% of the companies in the same industry.

AKRO has a Quick Ratio of 29.27. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 29.27, AKRO belongs to the best of the industry, outperforming 97.95% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	29.27
Quick Ratio	29.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.40% over the past year.

EPS 1Y (TTM)2.4%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-102.04%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 22.69% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-41.99%

EPS Next 2Y-24.49%

EPS Next 3Y-13.26%

EPS Next 5Y22.69%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AKRO's earnings are expected to decrease with -13.26% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-24.49%

EPS Next 3Y-13.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AKRO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AKERO THERAPEUTICS INC

NASDAQ:AKRO (4/26/2024, 7:00:00 PM)

After market: 19.42 -0.32 (-1.62%)

19.74

+0.81 (+4.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.35B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.15%
ROE	-28.35%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	29.27
Quick Ratio	29.27
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)2.4%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-41.99%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

AKERO THERAPEUTICS INC (AKRO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens